https://pipelinereview.com/kite-announces-yescarta-car-t-cell-therapy-improved-event-free-survival-by-60-over-chemotherapy-plus-stem-cell-transplant-in-second-line-relapsed-or-refractory-large-b-cell-lymphoma/